Upload
priorsmart
View
221
Download
0
Embed Size (px)
Citation preview
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
1/21
1650717_1.doc
Charles P. Kennedy
Natalie RicherLERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, NJ 07090-1497Tel: 908.654.5000
Fax: 908.654.7866
OF COUNSELJosh Krevitt
Joseph Evall
Jacob SherkowGIBSON, DUNN & CRUTCHER LLP
200 Park Avenue
New York, NY 10166-0193Tel: 212.351.2490
Fax: 212.351.6390Michael Sitzman
GIBSON, DUNN & CRUTCHER LLP555 Mission Street, Suite 3000
San Francisco, CA 94105
Tel: 415.393.8221Fax: 415.374.8454
Attorneys for Plaintiffs Medicis Pharmaceutical Corporation
and Dow Pharmaceutical Sciences, Inc.
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
MEDICIS PHARMACEUTICAL CORPORATIONand DOW PHARMACEUTICAL SCIENCES, INC.
Plaintiffs,
v.
STIEFEL LABORATORIES, INC. andGLAXOSMITHKLINE PLC,
Defendants.
::
:
:
::
:
::
x
Document Filed Electronically
Civil Action No.
District Judge:Magistrate Judge:
COMPLAINT AND DEMAND FOR TRIAL BY JURY
Plaintiffs Medicis Pharmaceutical Corporation ("Medicis") and Dow Pharmaceutical
Sciences, Inc. ("Dow"), by their attorneys, allege as follows:
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
2/21
1650717_1.doc 2
THE PARTIES
1. Medicis is a Delaware corporation with its principal place of business at 7720North Dobson Road, Scottsdale, Arizona 85256.
2. Dow is a California corporation with its principal place of business at 1330Redwood Way, Petaluma, California 94954.
3. On information and belief, Defendant Stiefel Laboratories, Inc. ("Stiefel") isincorporated in Delaware, has its principal place of business in Coral Gables, Florida, and has its
headquarters at 20 T.W Alexander Drive Research Triangle Park, North Carolina 27709.
4. On information and belief, Stiefel conducts business operations in the UnitedStates, including in the State of New Jersey.
5. On information and belief, Defendant GlaxoSmithKline Plc ("GSK") whollyowns Stiefel.
6. On information and belief, GSK is incorporated in the United Kingdom and has aregistered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
7. On information and belief, GSK conducts business operations throughout theUnited States, including in the State of New Jersey.
JURISDICTION
8. This action arises under 35 U.S.C. 271 and 281.9. This Court has subject matter jurisdiction over this action under 28 U.S.C.
1331 and 1338(a).
10. On information and belief, this Court has personal jurisdiction over Stiefelbecause Stiefel infringes United States Patent No. 6,387,383 (the '383 Patent) in this jurisdiction.
11. Venue is proper in this Court under 28 U.S.C. 1391(b) and (c).
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
3/21
1650717_1.doc 3
BACKGROUND
12. A copy of the 383 Patent is attached as Exhibit A.13. Dow is the owner by assignment of the '383 Patent, entitled "Topical
Low-Viscosity Gel Composition."
14. The 383 Patent is valid, unexpired, and duly issued by the U.S. Patent andTrademark Office.
15. Medicis is the exclusive licensee of the '383 Patent.16. One or more claims of the '383 Patent reads on a topical gel known as VeltinTM.17.
On information and belief, Stiefel makes, uses, offers to sell, sells, or imports
Veltin without authority of Plaintiffs.
18. On information and belief, Stiefel actively induces others to make, use, offer tosell, sell, or import Veltin without authority of Plaintiffs.
19. On information belief, Stiefel contributes to others making, using, offering to sell,selling, or importing Veltin without authority of Plaintiffs.
20. On information and belief, Stiefel willfully commits the acts described inparagraphs 17-19.
21. On information and belief, GSK makes, uses, offers to sell, sells, or importsVeltin.
22. On information belief, GSK actively induces others to make, use, offer to sell,sell, or import Veltin.
23. On information belief, GSK contributes to others making, using, offering to sell,selling, or importing Veltin.
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
4/21
1650717_1.doc 4
24. On information and belief, GSK willfully commits the acts described inparagraphs 21-23.
CLAIM I ____ INFRINGEMENT
(Against Stiefel)
25. Paragraphs 1-20 are incorporated by reference as if fully set forth herein.26. On information and belief, Stiefels making, use, offers to sell, sales, or
importation of VeltinTM directly infringes, literally or under the doctrine of equivalents, one or
more claims of the 383 Patent.
27. On information and belief, Stiefel actively induces others to infringe, literally orunder the doctrine of equivalents, one or more claims of the 383 Patent by manufacturing, using,
offering to sell, selling, or importing VeltinTM
.
28. On information and belief, Stiefel commits acts of contributory infringement,literally or under the doctrine of equivalents, of one or more claims of the 383 Patent by
manufacturing, using, offering to sell, selling, or importing VeltinTM.
CLAIM II ____ INFRINGEMENT
(Against GSK)
29. Paragraphs 1-24 are incorporated by reference as if fully set forth herein.30. On information and belief, GSKs making, use, offers to sell, sales, or importation
of VeltinTM directly infringes, literally or under the doctrine of equivalents, one or more claims
of the 383 Patent.
31. On information and belief, GSK actively induces others to infringe, literally orunder the doctrine of equivalents, one or more claims of the 383 Patent by manufacturing, using,
offering to sell, selling, or importing VeltinTM
.
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
5/21
1650717_1.doc 5
32. On information and belief, GSK commits acts of contributory infringement,literally or under the doctrine of equivalents, of one or more claims of the 383 Patent by
manufacturing, using, offering to sell, selling, or importing VeltinTM
.
RELIEF REQUESTED
Plaintiffs respectfully seek the following relief:
As to Claim I,
A. The entry of a judgment that Stiefels making, use, offers to sell, sales, orimportation of Veltin
TMdirectly infringes, induces infringement, or contributorily infringes one
or more claims of the 383 Patent;
B. An award of damages for Stiefels infringement of one or more claims of the 383Patent;
C. The entry of an injunction preventing Stiefel from further infringing one or moreclaims of the 383 Patent;
D. A declaration that this case is an exceptional and an award of increased damagesfor Stiefels willful infringement of one or more claims of the 383 Patent;
E. Pre- and post-judgment interest on any award of damages;F. Attorneys fees and costs pursuant to 35 U.S.C. 285 or as otherwise permitted
by law; and
G. Any other and further relief mandated by law or that this Court may deem just andproper.
And as to Claim II,
H. The entry of a judgment that GSKs manufacture, use, offers to sell, sales, orimportation of VeltinTM directly infringes, induces infringement, or contributorily infringes one
or more claims of the '383 Patent;
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
6/21
1650717_1.doc 6
I. An award of damages for GSKs infringement of one or more claims of the'383 Patent;
J. The entry of an injunction preventing GSK from further infringing one or moreclaims of the '383 Patent;
K. A declaration that this case is exceptional and an award of increased damages forGSKs willful infringement of one or more claims of the '383 Patent;
L. Pre- and post-judgment interest on any award of damages;M. Attorneys fees and costs pursuant to 35 U.S.C. 285 or as otherwise permitted
by law; and
N. Any other and further relief mandated by law or that this Court may deem just andproper.
JURY DEMAND
Plaintiffs demand a trial by jury on all issues so triable.
Respectfully submitted,
LERNER, DAVID, LITTENBERG,KRUMHOLZ & MENTLIK, LLP
Attorneys for Medicis Pharmaceutical
Corporation and Dow Pharmaceutical
Sciences , Inc.
Dated: March 20, 2012 By: s/ Charles P. KennedyCharles P. Kennedy
Tel: 908.654.5000
E-mail:[email protected]@ldlkm.com
OF COUNSEL:Josh Krevitt
Joseph Evall
Jacob Sherkow
Michael SitzmanGIBSON, DUNN & CRUTCHER LLP
mailto:[email protected]:[email protected]:[email protected]8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
7/21
1650717_1.doc 7
CERTIFICATION PURSUANT TO LOCAL CIVIL RULE 11.2
The undersigned hereby certifies, pursuant to Local Civil Rule 11.2, that with respect to
the matter in controversy herein, neither Medicis Pharmaceutical Corporation and DowPharmaceutical Sciences nor Medicis Pharmaceutical Corporation's and Dow Pharmaceutical
Sciences' attorney is aware of any other action pending in any court, or of any pending
arbitration or administrative proceeding, to which this matter is subject.
Dated: March 20, 2012 LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
Attorneys for Plaintiffs Medicis
Pharmaceutical Corporation and Dow
Pharmaceutical Sciences, Inc.
By: s/ Charles P. Kennedy
Charles P. Kennedy
Tel: 908.654.5000E-mail: [email protected]
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
8/21
EXHIBIT A
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
9/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
10/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
11/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
12/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
13/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
14/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
15/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
16/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
17/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
18/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
19/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
20/21
8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.
21/21